Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy

Journal of Immunotherapy

Volumn 36, Issue 2, 2013, Pages 79-81

  Brichard, Vincent G ^a   Louahed, Jamila ^a   Clay, Timothy M ^a  

^a GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSTIMULATING AGENT; MELANOMA ANTIGEN 3; T LYMPHOCYTE RECEPTOR;

ANTIGEN SPECIFICITY; CANCER REGRESSION; CARDIOVASCULAR DISEASE; CELL ENGINEERING; CELL THERAPY; CELL TRANSFER; GENE EXPRESSION; GENE THERAPY; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; MELANOMA; MYELOMA; NEUROTOXICITY; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIGENS, NEOPLASM; FEMALE; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL;

EID: 84874001209     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182829747     Document Type: Note

References (36)

1. Old LJ, Boyse EA, Stockert E. Typing of mouse leukemias by serological methods. Nature. 1964;201:777-779.
2. Knuth A, Danowski B, Oettgen HF, et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. PNAS. 1984;81: 3511-3515.
3. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
4. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotech. 2011;29: 550-557.
5. Dembić Z, Haas W, Weiss S, et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986;320:232-238.
6. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507-513.
7. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
8. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535-546.
9. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
10. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626.
11. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by non-self major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA. 1996;93:13114-13118.
12. Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced anti tumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66:8878-8886.
13. Holler PD, Holman PO, Shusta EV, et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA. 2000;97:5387-5392.
14. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;3:349-354.
15. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179:5845-5854.
16. Chlewicki LK, Holler PD, Monti BC, et al. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol. 2005;346:223-239.
17. Robbins PF, Li YF, El Gamil M, et al. Single and dual amino acid substitutions in TCR CDR scan enhance antigen-specific T cell functions. J Immunol. 2008;180:6116-6131.
18. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
19. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626.
20. Abbasi AM, Chester KA, MacPherson AJ, et al. Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J Pathol. 1992;168:405-411.
21. Chinnasamy N, Wargo JA, Yu Z, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A3 antigen superfamily in several types of cancer. J Immunol. 2011;186:685-696.
22. Van Den Eynde BJ, van der Bruggen PT. Cell defined tumor antigens. Curr Opin Immunol. 1997;9:684-693.
23. Jungbluth AA, Silva WA, Iversen K, et al. Expression of cancer-testis (CT) antigens in placenta. Cancer Immunol. 2007;24:7-15.
24. Jassim A, Ollier W, Payne A, et al. Analysis of HLA antigens on germ cells in human semen. Eur J Immunol. 1989;19: 1215-1220.
25. Blaschitz A, Hutter H, Dohr G. HLA class I protein expression in the human placenta. Early Pregnancy. 2001;5:67-69.
26. Finn OJ. Cancer immunology. N Engl J Med. 2008;358: 2704-2715.
27. Morgan RA, Chinnasamy N, Gros A, et al. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. (In press).
28. NIH RAC presentation: Update on Immunotherapy Trials for HIV and Cancer. June 19, 2012. http://oba.od.nih.gov/oba/RAC/meetings/June2012/1-TCRUpdate-June. pdf. Accessed October 23, 2012.
29. Kruit W, Suciu S, Dreno B, et al. Active immunization against the MAGE-A3 tumor-specific antigen in patients with metastatic melanoma: follow-up results from randomized phase II study (EORTC16032-18031). American Society of Clinical Oncology-47th Annual Meeting. 2011;29 (15 (May 20 Supplement)):abstract 8535.
30. Vansteenkiste J, Zielinski M, Linder A, et al. Phase II randomized study of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): 44 month follow-up, humoral and cellular immune response data. IASLC-ESMO European Lung Cancer Conference-1st. 2008;3(suppl 1):S55-S56, abstract 1480.
31. http://www.clinicaltrials.gov. Accessed October 26, 2012.
32. Segal L, Grosdidier E, Destexh E, et al. Repeated dose toxicity and local tolerance study with recMAGEA3+AS15 antigen specific cancer immunotherapeutic (ASCI) given intramuscularly to cynomolgus monkeys 2237 Poster Board-153.SOT 2012.
33. Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010;16:4892-4898.
34. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2-deoxycytidine. Cancer Res. 2004;64:9167-9171.
35. Becker JC, Gillitzer R, Brocker EB. A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing. Int J Cancer. 1994;58:346-348.
36. Schmid DA, Irving MB, Posevitz V, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol. 2010;184:4936-4946.